ERBB2 and breast carcinoma: Taken together, the foregoing data demonstrate that we have successfully overcome critical in vivo barriers to targeted delivery, penetration, specific accumulation, and retention of nanoimmunoconjugates in HER2+ breast cancer xenograft/orthotopic models using a renally-clearable particle imaging platform.